All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.

2017-10-03T08:09:52.000Z

FDA grants Adcetris® Breakthrough Therapy Designation for frontline advanced Hodgkin Lymphoma

Oct 3, 2017
Share:

Bookmark this article

On 2nd October 2017, Adcetris® (brentuximab vedotin [an antibody-drug conjugate directed against CD30]) in combination with chemotherapy was granted Breakthrough Therapy Designation (BTD) by the US Food and Drug Administration (FDA) for the frontline treatment of patients with advanced Classical Hodgkin Lymphoma (cHL).

The BTD was granted based on results from the phase III randomized ECHELON-1 (NCT01712490) study which is evaluating the combination of Adcetris® plus AVD doxorubicin [Adriamycin®], vinblastine, dacarbazine (A+AVD) compared to standard of care chemotherapy regimen (control arm) in patients with previously untreated advanced cHL. The primary endpoint of the study was Modified Progression Free Survival (mPFS) per Independent Review Facility (IRF).

Results from this phase III ECHELON-1 study showed that A+AVD significantly improved the mPFS compared to the control arm (HR = 0.770, P = 0.035). Full data of this study is to be presented at the  59th American Society of Hematology (ASH) Meeting and Exposition, Atlanta, GA, USA, from 9th–12th December 2017.

A supplemental Biologics License Application (BLA) for Adcetris® in combination with chemotherapy for advanced cHL is expected to be submitted to the FDA before the end of 2017.

  1. Street Insider. Seattle Genetics (SGEN) Announces FDA Breakthrough Therapy Designation for ADCETRIS in Frontline Advanced Hodgkin Lymphoma. 2017 Oct 2. https://www.streetinsider.com/Corporate+News/Seattle+Genetics+%28SGEN%29+Announces+FDA+Breakthrough+Therapy+Designation+for+ADCETRIS+in+Frontline+Advanced+Hodgkin+Lymphoma/13347345.html. [Accessed 2017 Oct 2].

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
60 votes - 48 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox